arrow
C

Christian Holm Hansen

medical research council clinical trials unit
H指数:41
被引数:7,098

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial

东非和南非以顺性别女性为主的人群中HIV暴露前预防中F/TAF与F/TDF的比较:一项随机、析因、非劣效性试验

2026-06-010
PRE
Unmeasured confounding and misclassification in studies estimating vaccine effectiveness against hospitalisation and death using electronic health records (EHRs): an evaluation of a multi-country European retrospective cohort study

未测量混杂和错分偏倚在利用电子健康记录(EHRs)评估疫苗对住院和死亡的保护效果研究中的影响:一项多国欧洲回顾性队列研究的评估

2025-12-170
OAAI
Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study

2023年秋季XBB.1.5 COVID-19加强针在2024年夏季于欧盟/欧洲经济区内的有效性:一项VEBIS电子健康记录网络研究

2025-11-280
OAAI
Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study

JN.1单价COVID-19疫苗接种在欧盟/欧洲经济区国家(2024年10月至2025年1月)的有效性:一项VEBIS电子健康记录网络研究

Vaccine
IF3.5
2025-09-190
PRE
Comparison of two methods for the estimation of COVID-19 vaccine effectiveness of the autumnal booster within the VEBIS-EHR network in 2022/23

2022/23年度在VEBIS-EHR网络中针对秋季加强针的两种COVID-19疫苗有效性估计方法的比较

2025-03-172
OAAI
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial

疫苗H56:IC31在降低HIV阴性、成功接受药物敏感型肺结核治疗成人中结核病复发率方面的免疫原性、安全性与有效性:一项双盲、随机、安慰剂对照的2b期试验

2025-03-050
PRE
Genome-based newborn screening for severe childhood genetic diseases has high positive predictive value and sensitivity in a NICU pilot trial
2024-12-011
PRE
Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselection
2024-12-011
PRE
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
2024-11-251
OA
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study

10月2023年11月,XBB.1.5单价新型冠状病毒肺炎疫苗在欧盟/欧洲经济区国家XBB.1.5主导时期的有效性: vebis-ehr网络研究

2024-04-233
OA